Brazil tears up Abbott deal, threatens to violate Kaletra patent

Brazil is again threatening to break Abbott's patent on Kaletra if it won't offer the country a deeper discount on the AIDS drug. Several Brazilian labs have reported to the government that they can manufacture and sell Kaletra for 41 cents per pill, far less than the $1.17 per pill that Abbott charges. A spokesperson for Abbott said the company had thought that it had already struck a fair deal to discount Kaletra, an antiretroviral, but that the company would continue to negotiate in good faith.

- read this article in The New York Times for more

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.